ArticleClinical case reports2025
Atypical Multiple Sclerosis Overlapping Features of Neuromyelitis Optica Spectrum Disorders (NMOSD).
Article in Clinical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Atypical Multiple Sclerosis Overlapping Features of Neuromyelitis Optica Spectrum Disorders (NMOSD).Clinical case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We aim to discuss the importance of accurately diagnosing atypical inflammatory demyelinating diseases (IDD), particularly neuromyelitis optica spectrum disorders (NMOSD), which exhibit similar pathological characteristics to multiple sclerosis (MS). An accurate diagnosis is crucial as the disease-modifying treatments (DMTs) used for MS can be ineffective or even exacerbate NMOSD. Our case was a 20-year-old man who presented with acute quadriparesis and hyperreflexia. Brain and cervical MRI revealed several T2-weighted hyperintensities in the periventricular and corticomedullary junction areas. The CSF analysis showed six oligoclonal bands restricted to the CSF, and the serum AQP4-IgG was negative. The patient was diagnosed with an atypical relapsing and remitting MS based on the 2017 revised McDonald criteria and was treated with intravenous methylprednisolone and therapeutic plasma exchange. Eventually, his EDSS score improved from 8.5 to 3 after treatment with rituximab. Accurate diagnosis of atypical cases of IDD is not only to prevent potential harm associated with misdirected therapies but also to promptly initiate the most effective treatment. Vigilance for diagnostic red flags in MS is particularly important given its clinical and radiographic overlap with NMOSD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.